Target
Glucagon receptor
glucagon receptor
Aliases: GCGR · GCG-R
Activation increases hepatic glucose output and energy expenditure; biased/co-agonist approaches aim to preserve lipid oxidation and satiety without hyperglycemia.
Mechanism summary
Activation increases hepatic glucose output and energy expenditure; biased/co-agonist approaches aim to preserve lipid oxidation and satiety without hyperglycemia.
Family: G-protein coupled receptor (GPCR), class B
Related indications
Assets targeting this mechanism
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Retatrutide | Phase 3 | Eli Lilly |
| Mazdutide | Phase 3 | Eli Lilly |
| Survodutide | Phase 2 | Boehringer Ingelheim, Zealand Pharma |
| Pemvidutide | Phase 2 | Eli Lilly |
| Efinopegdutide | Phase 2 | Eli Lilly |
Competing assets
5 assets are mapped to Glucagon receptor. View the asset table above to compare stages and sponsors.